Clinical Trials · NCT03798080

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Name: Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lixisenatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Sanofi
Enrollment: 426
Start date: Feb 2019
Locations: 45 sites, China
Primary endpoint: Change in HbA1c

View Lixisenatide compound reference